Cerebral Palsy Research Program Authorization Act of 2025
- Bill Number
- H.R. 2178
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-18: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-04-24T08:07:14Z
AI-Generated Summary
Purpose
The Cerebral Palsy Research Program Authorization Act of 2025 aims to advance scientific understanding and management of cerebral palsy—a group of lifelong motor disorders—by authorizing a federal research program. It seeks to address gaps in diagnosis, treatment, causes, and lifelong impacts, ultimately improving outcomes for affected individuals and reducing associated societal costs.
Key Provisions
- Findings Section: Outlines key facts about cerebral palsy, including its prevalence (affecting over 1 million Americans and 17 million worldwide), unknown causes in most cases, common co-occurring conditions (e.g., epilepsy, intellectual disabilities), higher vulnerability to illnesses like the flu or COVID-19, lack of standardized care practices, and massive economic burdens (e.g., over $13.5 billion in lifetime medical costs for those born in 2000 alone, plus $35 billion in lost productivity).
- Research Program (New Section 317C-1 of the Public Health Service Act):
- Authorizes the Secretary of Health and Human Services (HHS), through the Director of the Centers for Disease Control and Prevention (CDC), to conduct or fund research on cerebral palsy. This includes:
- Studies on promising diagnostic and treatment methods.
- Factors that could reduce its occurrence.
- Health care and societal costs.
- Mandates public health surveillance (ongoing monitoring of the condition's spread and patterns).
- Supports education and training for health professionals and the public on causes, prevalence, diagnosis, treatment, and lifelong effects.
- Technical Assistance: HHS may provide support (directly or via grants/contracts) to public and nonprofit organizations to advance this research.
- Evaluations: Requires assessments of the program's effectiveness, including impacts on different demographic groups (e.g., by age, race, or location).
- Funding: Authorizes $5 million annually for fiscal years 2026 through 2031 to implement the program.
Significant Changes to Existing Law
- Amends Title III of the Public Health Service Act (42 U.S.C. 247b et seq.) by inserting a new section (317C-1) specifically dedicated to cerebral palsy research.
- This is the first dedicated federal authorization for a comprehensive cerebral palsy research program under the CDC, filling a previous gap where no such targeted, coordinated effort existed in statute. Prior to this, research on cerebral palsy may have occurred sporadically through broader public health or disability initiatives, but without dedicated funding or focus.
Potential Impacts
- Government Agencies: Expands CDC and HHS responsibilities by establishing a new research mandate, requiring coordination with other federal agencies and partners. This could strain resources if funding is not fully appropriated but also positions the CDC as a leader in neurodevelopmental disorder research.
- Citizens: Individuals with cerebral palsy (over 1 million in the U.S.) and their families may benefit from improved diagnostics, treatments, and preventive strategies, potentially leading to better quality of life, reduced health risks, and lower long-term costs. Broader public health education could enhance early intervention and support services.
- International Relations: Minimal direct impact, though global findings (noting 17 million affected worldwide) could inform international collaborations on disability research, indirectly supporting U.S. leadership in global health initiatives.
- Societal/Economic: Could yield cost savings by mitigating prevalence and improving care efficiency, addressing the bill's noted $48.5 billion+ annual burden from medical, productivity, and wage losses.
Main Stakeholders Affected
- Individuals with Cerebral Palsy and Families: Primary beneficiaries through potential advances in care and support.
- Healthcare Professionals and Researchers: Gain access to funded programs, training, and data for better practices.
- Nonprofit and Public Entities: Eligible for technical assistance and grants to conduct or support research.
- Federal Agencies (HHS/CDC): Responsible for program implementation, surveillance, and evaluations.
- Taxpayers and Policymakers: Bear the cost of authorized appropriations while potentially reaping long-term economic benefits from research outcomes.
Notable Legal, Constitutional, or Political Implications
- Legal: Establishes a clear statutory framework for cerebral palsy research under existing public health authorities, with built-in accountability via evaluations. Funding is authorized but not mandatory (subject to annual appropriations), which is standard for such bills and avoids automatic spending mandates.
- Constitutional: Aligns with Congress's enumerated powers under Article I (e.g., taxing and spending for general welfare, regulating interstate commerce in health matters). No apparent conflicts with federalism, as it focuses on national research coordination without overriding state health programs.
- Political: Bipartisan introduction (by Reps. Cohen, Fitzpatrick, Cleaver, and Norton) signals broad support for disability-focused public health investment. It highlights neglected areas in pediatric and lifelong disability care, potentially influencing future funding debates or expansions to other neurodevelopmental conditions. No controversial elements like mandates on private entities, reducing political friction.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (8)
Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Cleaver, Emanuel [D-MO-5], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. LaHood, Darin [R-IL-16], Rep. Gottheimer, Josh [D-NJ-5], Rep. Sewell, Terri A. [D-AL-7], Rep. Tonko, Paul [D-NY-20]
Recent Actions
- 2025-03-18: Referred to the House Committee on Energy and Commerce.
- 2025-03-18: Introduced in House
- 2025-03-18: Introduced in House
Bill Versions
- Cerebral Palsy Research Program Authorization Act of 2025 — issued 2025-03-18 — PDF (5 pages)